Schedule M: Over 100 Pharma MSMEs in Telangana on the Brink of Closure

The Revised Schedule M, a set of GMP guidelines for pharmaceutical production, has been a game-changer for the industry.

561
Schedule-M
Schedule-M

Last Updated on August 1, 2024 by The Health Master

Schedule M

The pharmaceutical manufacturing landscape in Telangana is on the verge of a seismic shift due to revised Schedule M compliance.

Over a hundred Micro, Small, and Medium Enterprises (MSMEs) in the state are poised to shutter their operations within the next three months, as the stringent requirements of the Revised Schedule M prove insurmountable.

Schedule M Compliance: A Mountain to Climb

The Revised Schedule M, a set of Good Manufacturing Practices (GMP) guidelines for pharmaceutical production, has been a game-changer for the industry.

While larger pharma companies have managed to adapt to the new norms, smaller players are struggling to keep their heads above water.

  • Massive Investment: Upgrading facilities to meet Schedule M standards requires a hefty investment of Rs. 5 to 10 crore per unit.
  • Revenue Crunch: MSMEs are facing a dire financial situation, with many unable to generate the minimum Rs. 50 crore annual turnover necessary to sustain operations after compliance.

Industry in Distress: A Cry for Help

Faced with an uncertain future, the Telangana chapter of the Indian Drug Manufacturers Association (IDMA) has sounded the alarm.

President J Rajamouli led a delegation to the Director-General of Drugs Control Administration, seeking a temporary reprieve from inspections.

  • Intense Scrutiny: Drug control officials have been conducting frequent inspections, adding to the industry’s woes.
  • Temporary Relief: While the DG has agreed to halt inspections until December 2024, the long-term outlook remains bleak.

No Extension in Sight: A Do-or-Die Situation

The Central Drugs Standard Control Organization (CDSCO) has shown no inclination to extend the deadline for Schedule M compliance.

This leaves MSMEs with a stark choice: adapt or perish.

  • High Failure Rate: A staggering 36% of inspected manufacturing units have been forced to close due to non-compliance.
  • Industry-Wide Plea: Pharmaceutical associations across India have urged the CDSCO for a one-year extension, but their requests have fallen on deaf ears.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news